Now showing items 1-10 of 21
Evaluation of amonafide in disseminated malignant melanoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1993-06)
Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, ...
Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 1998-09)
Purpose : We have reported previously that the expression of E. coli dUTPase (dutE) can protect HT29 cells from 5-fluorodeoxyuridine (FdUrd)-induced DNA fragmentation and cytotoxicity. In the study reported here, we further ...
An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs
(Springer-Verlag, 1993-11)
Aclarubicin is an anthracycline antibiotic that differs from doxorubicin in its structure, mechanism of action, and preclinical toxicity profile, especially its reduced cardiotoxicity. We therefore conducted a side-by-side ...
Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 1997-12)
Purpose : Regional therapy of primary or metastatic liver cancer with low hepatic extraction ratio drugs such as doxorubicin is constrained by development of systemic toxicity. To examine the effect of augmentation of ...
Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-02)
Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there ...
Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells
(Springer-Verlag; Springer-Verlag Berlin Heidelberg, 1996-02)
The relationship between cell cycle progression and induction of DNA double-strand breaks and cytotoxicity by exposure to fluorodeoxyuridine (FdUrd) was studied in HT29 human colon cancer cells. Fractionation of drug-treated ...
Evaluation of menogaril in renal cell carcinoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-03)
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m 2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial ...
Phase II trial of N-methylformamide in lung cancer
(Kluwer Academic Publishers; Springer Science+Business Media, 1992-08)
Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-03)
Methylglyoxal bis-guanylhydrazone (MGBG), a potent inhibitor of polyamine synthesis, has demonstrated single agent activity against a number of tumor types including malignant lymphomas and head and neck, esophageal and ...
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma
(Kluwer Academic Publishers; Springer Science+Business Media, 1995-06)
Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma. This paper presents results of a Phase II clinical study of merbarone in patients with biopsy ...